|
1
|
Liu Y, Zhang Z, Xi P, Chen R, Cheng X, Liu J, Zhu Q, Nie Y, Sun T, Gong B, Wang S. Systematic analysis of RNASET2 gene as a potential prognostic and immunological biomarker in clear cell renal cell carcinoma. BMC Cancer 2023; 23:837. [PMID: 37679715 PMCID: PMC10483861 DOI: 10.1186/s12885-023-11356-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 08/31/2023] [Indexed: 09/09/2023] Open
Abstract
BACKGROUND RNASET2 has been identified as an oncogene with anti-angiogenic and immunomodulatory effects in a variety of cancers, but its function in clear cell renal cell carcinoma (ccRCC) is still not well understood. METHODS The RNASET2 expression matrix was extracted from the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets and analyzed for diagnostic and prognostic value. RNASET2 mRNA expression was detected by quantitative polymerase chain reaction (qPCR) in ccRCC patients and renal cancer cell lines. Wound healing assay, transwell assay, western blotting, and tube formation assays were used to evaluate the function of RNASET2 in renal cancer in vitro. In addition, transcriptome sequencing was performed on knockdown RNASET2 kidney cancer cells to analyze their potential signaling pathways. Moreover, the immune microenvironment and mutational status were evaluated to predict the potential mechanisms of RNASET2 involvement in renal cancer progression. Sensitivity to common chemotherapeutic and targeted agents was assessed according to the Genomics of Drug Sensitivity in Cancer (GDSC) database. RESULTS RNASET2 expression was significantly upregulated in ccRCC tissues and renal cancer cell lines, predicting poor prognosis for patients. In vitro experiments showed that silencing RNASET2 inhibited the migration and pro-angiogenic ability of renal cancer cells. Transcriptome sequencing suggested its possible involvement in the remodeling of the immune microenvironment in renal cell carcinoma. Furthermore, bioinformatics analysis and immunohistochemical staining showed that RNASET2 was positively correlated with the infiltration abundance of regulatory T cells. Finally, we mapped the mutational landscape of RNASET2 in ccRCC and found its predictive value for drug sensitivity. CONCLUSIONS Our results suggest that RNASET2 is a promising biomarker and therapeutic target in ccRCC.
Collapse
Affiliation(s)
- Yifu Liu
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Zhicheng Zhang
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Ping Xi
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Ru Chen
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Xiaofeng Cheng
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Ji Liu
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Qiqi Zhu
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Yechen Nie
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China
| | - Ting Sun
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
| | - Binbin Gong
- Department of Urology, The First Affiliated Hospital of Nanchang University, No.17, Yongwai Center Street, Donghu District, Nanchang, 330006, Jiangxi, China.
| | - Siyuan Wang
- Department of Urology, Sichuan Cancer Hospital School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Chengdu, 610041, Sichuan, China.
| |
Collapse
|
|
2
|
Kadomoto S, Izumi K, Hiratsuka K, Nakano T, Naito R, Makino T, Iwamoto H, Yaegashi H, Shigehara K, Kadono Y, Nakata H, Saito Y, Nakagawa-Goto K, Mizokami A. Reply to Comment on "Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis" Cancers 2020 12, 89. Cancers (Basel) 2020; 12:E354. [PMID: 32033135 PMCID: PMC7073159 DOI: 10.3390/cancers12020354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 01/30/2020] [Accepted: 01/31/2020] [Indexed: 11/17/2022] Open
Abstract
We appreciate Zins and Abraham [1] commenting on our paper studying the role of the CCL20-CCR6 axis on renal cell carcinoma (RCC) cells [2]. As they pointed out, our study has certain limitations. Although M1- and M2-types cannot be separated clearly and a consecutive change of character might exist between them, it has been reported that plural specific markers express on M1- and M2-types. Unfortunately, a definite difference between M1 and M2 macrophages was not confirmed in our study. For more differentiation, multiple stimulations, such as suggested in the comments of Zins and Abraham, might be needed. Hence, we needed to expediently use "M1-like" and "M2-like" to mention specific status of these macrophage-like cells. Meanwhile, CCL20 expression levels of M2-like-THP-1 cells co-cultured with RCC cells were dramatically increased compared with parental THP-1 cells, indicating that certain stimulations within the tumor microenvironment rather than theoretical stimulations make macrophages differentiated; however, further studies are needed to clarify this mechanism using a more appropriate co-culture system mimicking the tumor microenvironment. Immunohistochemistry of CCL20 and M2 markers will help to better understand the role of tissue infiltrating macrophages, even tissue CD68 staining intensity itself was reported to correlate with prognosis of RCC patients [3]. [...].
Collapse
Affiliation(s)
- Suguru Kadomoto
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Kouji Izumi
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Kaoru Hiratsuka
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Taito Nakano
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Renato Naito
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Tomoyuki Makino
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Hiroaki Iwamoto
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Hiroshi Yaegashi
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Kazuyoshi Shigehara
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Yoshifumi Kadono
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| | - Hiroki Nakata
- Department of Histology and Cell Biology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan;
| | - Yohei Saito
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Science, Kanazawa University, Kanazawa 920-1192, Japan
| | - Kyoko Nakagawa-Goto
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Science, Kanazawa University, Kanazawa 920-1192, Japan
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan; (S.K.); (K.H.); (T.N.); (R.N.); (T.M.); (H.I.); (H.Y.); (K.S.); (Y.K.)
| |
Collapse
|